Relmada Q1 FY26 net loss widens to $19.1 million; R&D expense falls to $8.1 million

RELMADA THERAPEUTICS INC

RELMADA THERAPEUTICS INC

RLMD

0.00
  • Relmada Therapeutics posted a first-quarter net loss of USD 19.1 million, or USD 0.22 per share, versus a net loss of USD 17.6 million, or USD 0.58 per share, a year earlier.
  • Research and development expense fell 32.5% to USD 8.1 million, while general and administrative expense climbed 81% to USD 11.4 million.
  • Cash, cash equivalents, and short-term investments rose to USD 234 million as of March 31, 2026, up from about USD 93 million at Dec. 31, 2025.
  • Company expects current resources to fund operations through 2029, including completion of NDV-01 Phase 3 RESCUE program, with IND filing and Phase 3 initiation targeted for mid-2026.
  • Management highlighted 12-month Phase 2 NDV-01 data showing a 95% complete response rate at any time and 76% at 12 months in high-risk NMIBC, including 94% and 80% in BCG-unresponsive patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.